---
title: "GuoChuang released its performance for the first half of the year, with a net loss attributable to the parent company of 63.979 million yuan, an increase of 224.96%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253475150.md"
description: "GuoChuang released its semi-annual report for 2025, with operating revenue of 498 million yuan, a year-on-year decrease of 24.37%. The net loss attributable to shareholders was 63.979 million yuan, a year-on-year increase of 224.96%. The net loss after deducting non-recurring gains and losses was 64.5556 million yuan, a year-on-year increase of 91.75%. The basic loss per share was 0.22 yuan"
datetime: "2025-08-18T12:57:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253475150.md)
  - [en](https://longbridge.com/en/news/253475150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253475150.md)
generator: "portal-rs"
---

# GuoChuang released its performance for the first half of the year, with a net loss attributable to the parent company of 63.979 million yuan, an increase of 224.96%

According to the Zhitong Finance APP, GuoChuang (300520.SZ) released its semi-annual report for 2025, showing an operating income of 498 million yuan, a year-on-year decrease of 24.37%. The net loss attributable to shareholders of the listed company was 63.979 million yuan, a year-on-year increase of 224.96%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 64.5556 million yuan, a year-on-year increase of 91.75%. The basic loss per share was 0.22 yuan

### Related Stocks

- [300520.CN](https://longbridge.com/en/quote/300520.CN.md)

## Related News & Research

- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [Lyntris valued at $1.8 billion after shares fall in New York debut](https://longbridge.com/en/news/296376207.md)
- [Lundbeck Foundation unit Lundbeckfond Invest launches voluntary exchange offer for Lundbeck A-shares](https://longbridge.com/en/news/296304407.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [GRAINS-Soybeans near three-week high on China demand, crop worries](https://longbridge.com/en/news/296295616.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**